Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
Status:
Withdrawn
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
GAX represents a novel approach to the development of cancer chemotherapy agents in
pancreatic cancer and is based upon extensive laboratory investigations for the induction of
apoptosis in pancreatic carcinoma cells.